Lyxumia lixisenatide regulatory update

FDA accepted for review an NDA from Sanofi for lixisenatide to treat Type II diabetes. Sanofi submitted the NDA in late July (see BioCentury, Sept. 16, 2013). The glucagon-like peptide-1 receptor ( G...